Adverse events
| . | Iron group . | Placebo group . | P . |
|---|---|---|---|
| All adverse events | |||
| Number of patients reporting events, n (%) | 23 (53%) | 31 (66%) | ns |
| Total number of adverse events, n | 52 | 53 | ns |
| Number of serious adverse events, n | 1 | 1 | |
| Appendicitis | 1 | 0 | |
| Traffic accident | 0 | 1 | |
| Drug-associated adverse events | |||
| Number of patients reporting events, n | 9 (21%) | 3 (7%) | .05 |
| Total number of adverse events, n | 17 | 4 | ns |
| Nausea | 6 | 1 | |
| Chills | 4 | 0 | |
| Headache | 3 | 1 | |
| Dizziness | 1 | 1 | |
| Chest pain | 1 | 0 | |
| Dysaesthesia | 1 | 0 | |
| Dysgeusia | 1 | 0 | |
| Diarrhea | 0 | 1 |
| . | Iron group . | Placebo group . | P . |
|---|---|---|---|
| All adverse events | |||
| Number of patients reporting events, n (%) | 23 (53%) | 31 (66%) | ns |
| Total number of adverse events, n | 52 | 53 | ns |
| Number of serious adverse events, n | 1 | 1 | |
| Appendicitis | 1 | 0 | |
| Traffic accident | 0 | 1 | |
| Drug-associated adverse events | |||
| Number of patients reporting events, n | 9 (21%) | 3 (7%) | .05 |
| Total number of adverse events, n | 17 | 4 | ns |
| Nausea | 6 | 1 | |
| Chills | 4 | 0 | |
| Headache | 3 | 1 | |
| Dizziness | 1 | 1 | |
| Chest pain | 1 | 0 | |
| Dysaesthesia | 1 | 0 | |
| Dysgeusia | 1 | 0 | |
| Diarrhea | 0 | 1 |
P values were calculated with the χ2 test or the Mann Whitney U test (number of events per patient).
ns indicates not significant and no trend (P > .10).